Monoclonal Antibody to Parkinson Disease Protein 7 (PARK7) is a premium-quality life science research product supplied by Torvigen for laboratory and scientific applications.
RPL059Hu02-Recombinant Parkinson Disease Protein 7 (PARK7)
Recommended Usage
Western blotting: 0.5-2μg/mL; < br/> Immunohistochemistry: 5-20μg/mL; < br/> Immunocytochemistry: 5-20μg/mL; < br/> Optimal working dilutions must be determined by end user.
